Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence

Clinical Research in Cardiology

Volumn 103, Issue 11, 2014, Pages 855-886

  Budzyński, Jacek ^a,b   Koziński, Marek ^a   Kłopocka, Maria ^a   Kubica, Julia Maria ^a   Kubica, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Division of Vascular Diseases and Internal Medicine   (Poland)

Author keywords

Acute coronary syndrome; Bleeding complication; Coronary artery disease; Helicobacter pylori; Platelets

Indexed keywords

EID: 84943589420     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-014-0720-4     Document Type: Review

References (160)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2013) Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127(1):143–152. doi:10.1161/CIR.0b013e318282ab8f
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952
3. Libby P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32(9):2045–2051. doi:10.1161/ATVBAHA.108.179705
4. Krintus M, Kozinski M, Stefanska A, Sawicki M, Obonska K, Fabiszak T, Kubica J, Sypniewska G (2012) Value of C-reactive protein as a risk factor for acute coronary syndrome: a comparison with apolipoprotein concentrations and lipid profile. Mediators Inflamm 2012:419804. doi:10.1155/2012/419804
5. Koziński M, Krzewina-Kowalska A, Kubica J, Żbikowska-Gotz M, Dymek G, Piasecki R, Sukiennik A, Grześk G, Bogdan M, Chojnicki M, Dziedziczko A, Sypniewska G (2005) Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis - comparison with stable and unstable angina. Inflamm Res 54(5):187–193
6. Kubica J, Koziński M, Krzewina-Kowalska A, Żbikowska-Gotz M, Dymek G, Sukiennik A, Piasecki R, Bogdan M, Grześk G, Chojnicki M, Dziedziczko A, Sypniewska G (2005) Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int J Mol Med 16(1):173–180
7. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group (2012) Management of Helicobacter pylori infection—the Maastricht IV/florence consensus report. Gut 61(5):646–664. doi:10.1136/gutjnl-2012-302084
8. Izzotti A, Durando P, Ansaldi F, Gianiorio F, Pulliero A (2009) Interaction between Helicobacter pylori, diet, and genetic polymorphisms as related to non-cancer diseases. Mutat Res 667(1–2):142–157. doi:10.1016/j.mrfmmm.2009.02.002
9. Kanbay M, Gür G, Yücel M, Yilmaz U, Muderrisoglu H (2005) Helicobacter pylori seroprevalence in patients with coronary artery disease. Dig Dis Sci 50(11):2071–2074
10. Franceschi F, Niccoli G, Ferrante G, Gasbarrini A, Baldi A, Candelli M, Feroce F, Saulnier N, Conte M, Roccarina D, Lanza GA, Gasbarrini G, Gentiloni SN, Crea F (2009) CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis 202(2):535–542. doi:10.1016/j.atherosclerosis.2008.04.051
11. Tanigawa T, Watanabe T, Nadatani Y, Otani K, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Arakawa T (2011) Gastrointestinal bleeding after percutaneous coronary intervention. Digestion 83(3):153–160. doi:10.1159/000321813
12. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ, American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (2008) ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 52(18):1502–1517. doi:10.1016/j.jacc.2008.08.002
13. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF, ACCF/ACG/AHA (2010) ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 56(24):2051–2066. doi:10.1016/j.jacc.2010.09.010
14. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Muñoz E (2004) Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 19(6):617–629
15. Huang JQ, Sridhar S, Hunt RH (2002) Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359(9300):14–22
16. Iwamoto J, Saito Y, Honda A, Matsuzaki Y (2013) Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. World J Gastroenterol 19(11):1673–1682. doi:10.3748/wjg.v19.i11.1673
17. Vergara M, Catalán M, Gisbert JP, Calvet X (2005) Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21(12):1411–1418
18. Chan FKL, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ (2013) Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 144(3):528–535. doi:10.1053/j.gastro.2012.12.038
19. Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS (2010) Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 32(7):831–839. doi:10.1111/j.1365-2036.2010.04415.x
20. Leung Ki EL, Chan FK (2012) Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice. Best Pract Res Clin Gastroenterol 26(2):163–172. doi:10.1016/j.bpg.2012.01.006
21. Elizalde JI, Pérez-Pujol S, Heras M, Sionis A, Casanovas N, Martorell T, Lozano M, González J, Escolar G, Sanz G, Piqué JM (2004) Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes. Helicobacter 9(6):681–689
22. Figura N, Palazzuoli A, Vaira D, Campagna M, Moretti E, Iacoponi F, Giordano N, Clemente S, Nuti R, Ponzetto A (2014) Cross-sectional study: CagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. J Clin Pathol 67(3):251–257. doi:10.1136/jclinpath-2013-201743
23. Iwao Y, Takano T, Taneike I, Reva I, Isobe H, Zhang HM, Nishiyama A, Yamamoto T (2013) Anti-Helicobacter pylori actions of CV-6209, a platelet-activating factor receptor antagonist. J Gen Appl Microbiol 59(2):147–152
24. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF, On behalf of ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis (2013) Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 34(23):1708–1713. doi:10.1093/eurheartj/eht042
25. Kasprzak M, Koziński M, Kubica A, Navarese EP, Grześk G, Kubica J (2012) An overview of methods dedicated to protection of the digestive tract in patients treated with aspirin. Focus on clinical effectiveness and antiplatelet properties. Kardiol Pol 70(4):405–413
26. Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A (2011) Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 32(4):459–466. doi:10.1007/s11239-011-0611-8
27. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC (1994) Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 71(5):437–439
28. Kusters JG, Kuipers EJ (1999) Helicobacter and atherosclerosis. Am Heart J 138(5 Pt 2):S523–S527
29. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ et al (1995) Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 311(7007):711–714
30. Di Rienzo TA, D'Angelo G, Ojetti V, Campanale MC, Tortora A, Cesario V, Zuccalà G, Franceschi F (2013) 13C-Urea breath test for the diagnosis of Helicobacter pylori infection. Eur Rev Med Pharmacol Sci 17(Suppl 2):51–58
31. Eskandarian R, Ghorbani R, Shiyasi M, Momeni B, Hajifathalian K, Madani M (2012) Prognostic role of Helicobacter pylori infection in acute coronary syndrome: a prospective cohort study. Cardiovasc J Afr 23(3):131–135. doi:10.5830/CVJA-2011-016
32. Rupprecht HJ, Blankenberg S, Bickel C, Rippin G, Hafner G, Prellwitz W, Schlumberger W, Meyer J, AutoGene Investigators (2001) Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 104(1):25–31
33. Lin HJ, Lo WC, Perng CL, Li AF, Tseng GY, Sun IC, Ou YH (2004) Helicobacter pylori stool antigen test in patients with bleeding peptic ulcers. Helicobacter 9(6):663–668
34. Pasceri V, Patti G, Cammarota G, Pristipino C, Richichi G, Di Sciascio G (2006) Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. Am Heart J 151(6):1215–1222
35. Zhang S, Guo Y, Ma Y, Teng Y (2008) Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review. Chin Med J (Engl) 121(10):946–951
36. Niccoli G, Franceschi F, Cosentino N, Giupponi B, De Marco G, Merra G, Conte M, Montone RA, Ferrante G, Bacà M, Gasbarrini A, Silveri NG, Crea F (2010) Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coron Artery Dis 21(4):217–221. doi:10.1097/MCA.0b013e3283399f36
37. Jafarzadeh A, Nemati M, Tahmasbi M, Ahmadi P, Rezayati MT, Sayadi AR (2011) The association between infection burden in Iranian patients with acute myocardial infarction and unstable angina. Acta Med Indones 43(2):105–111
38. Strachan DP, Mendall MA, Carrington D, Butland BK, Yarnell JW, Sweetnam PM, Elwood PC (1998) Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the cCaerphilly prospective heart disease study. Circulation 98(13):1286–1290
39. Danesh J (1999) Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies. Am Heart J 138(5 Pt 2):S434–S437
40. Glynn MK, Friedman CR, Gold BD, Khanna B, Hutwagner L, Iihoshi N, Revollo C, Quick R (2002) Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors. Clin Infect Dis 35(9):1059–1065
41. Pellicano R, Mladenova I, Broutet N, Salmi LR, Mégraud F (1999) Is there an association between Helicobacter pylori infection and coronary heart disease? Eur J Epidemiol 15(7):611–619
42. Rogha M, Dadkhah D, Pourmoghaddas Z, Shirneshan K, Nikvarz M, Pourmoghaddas M (2012) Association of helicobacter pylori infection with severity of coronary heart disease. ARYA Atheroscler 7(4):138–141
43. Rogha M, Nikvarz M, Pourmoghaddas Z, Shirneshan K, Dadkhah D, Pourmoghaddas M (2012) Is Helicobacter pylori infection a risk factor for coronary heart disease? ARYA Atheroscler 8(1):5–8
44. Kowalski M, Konturek PC, Pieniazek P, Karczewska E, Kluczka A, Grove R, Kranig W, Nasseri R, Thale J, Hahn EG, Konturek SJ (2001) Prevalence of Helicobacter pylori infection in coronary artery disease and effect of its eradication on coronary lumen reduction after percutaneous coronary angioplasty. Dig Liver Dis 33(3):222–229
45. Celik T, Iyisoy A, Yuksel UC (2010) Possible pathogenetic role of Helicobacter pylori infection in cardiac syndrome X. Int J Cardiol 142(2):193–194. doi:10.1016/j.ijcard.2008.11.110
46. Rasmi Y, Raeisi S (2009) Possible role of Helicobacter pylori infection via microvascular dysfunction in cardiac syndrome X. Cardiol J 16(6):585–587
47. Rasmi Y, Seyyed-Mohammadzad MH (2012) Frequency of Helicobacter pylori and cytotoxine associated gene A antibodies in patients with cardiac syndrome X. J Cardiovasc Dis Res 3(1):19–21. doi:10.4103/0975-3583.91597
48. Budzyński J (2011) The favourable effect of Helicobacter pylori eradication therapy in patients with recurrent angina-like chest pain and non-responsive to proton pump inhibitors: a preliminary study. Arch Med Sci 7(1):73–80. doi:10.5114/aoms.2011.20607
49. Sandifer QD, Vuilo S, Crompton G (1996) Association of Helicobacter pylori infection with coronary heart disease. Association may not be causal. BMJ 312(7025):251
50. Danesh J, Peto R (1998) Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 316(7138):1130–1132
51. Saleh N, Svane B, Jensen J, Hansson LO, Nordin M, Tornvall P (2005) Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris. Am Heart J 149(5):876–882
52. Koenig W, Rothenbacher D, Hoffmeister A, Miller M, Bode G, Adler G, Hombach V, März W, Pepys MB, Brenner H (1999) Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. Circulation 100(23):2326–2331
53. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL, Fedeli G, Gasbarrini G, Maseri A (1998) Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 97(17):1675–1679
54. Gunn M, Stephens JC, Thompson JR, Rathbone BJ, Samani NJ (2000) Significant association of cagA positive Helicobacter pylori strains with risk of premature myocardial infarction. Heart 84(3):267–271
55. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Hawkey C, Atherton J (2000) Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men. Circulation 101(14):1647–1652
56. Stone AF, Risley P, Markus HS, Butland BK, Strachan DP, Elwood PC, Mendall MA (2001) Ischaemic heart disease and Cag A strains of Helicobacter pylori in the Caerphilly heart disease study. Heart 86(5):506–509
57. Kinjo K, Sato H, Sato H, Shiotani I, Kurotobi T, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, Sasaki T, Kohama A, Abe Y, Morita H, Kubo M, Takeda H, Hori M, Osaka Acute Coronary Insufficiency Study (OACIS) Group (2002) Prevalence of Helicobacter pylori infection and its link to coronary risk factors in Japanese patients with acute myocardial infarction. Circ J 66(9):805–810
58. Singh RK, McMahon AD, Patel H, Packard CJ, Rathbone BJ, Samani NJ (2002) Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease. Heart 88(1):43–46
59. Aceti A, Are R, Sabino G, Fenu L, Pasquazzi C, Quaranta G, Zechini B, Terrosu P (2004) Helicobacter pylori active infection in patients with acute coronary heart disease. J Infect 49(1):8–12
60. Sheehan J, Kearney PM, Sullivan SO, Mongan C, Kelly E, Perry IJ (2005) Acute coronary syndrome and chronic infection in the Cork coronary care case-control study. Heart 91(1):19–22
61. Miyazaki M, Babazono A, Kadowaki K, Kato M, Takata T, Une H (2006) Is Helicobacter pylori infection a risk factor for acute coronary syndromes? J Infect 52(2):86–91
62. Jin SW, Her SH, Lee JM, Yoon HJ, Moon SJ, Kim PJ, Baek SH, Seung KB, Kim JH, Kang SB, Kim JH, Kim KY (2007) The association between current Helicobacter pylori infection and coronary artery disease. Korean J Intern Med 22(3):152–156
63. Tamer GS, Tengiz I, Ercan E, Duman C, Alioglu E, Turk UO (2009) Helicobacter pylori seropositivity in patients with acute coronary syndromes. Dig Dis Sci 54(6):1253–1256. doi:10.1007/s10620-008-0482-9
64. Khodaii Z, Vakili H, Ghaderian SM, Najar RA, Panah AS (2011) Association of Helicobacter pylori infection with acute myocardial infarction. Coron Artery Dis 22(1):6–11. doi:10.1097/MCA.0b013e3283402360
65. Azarkar Z, Jafarnejad M, Sharifzadeh G (2011) The relationship between Helicobacter pylori infection and myocardial infarction. Caspian J Intern Med 2(2):222–225
66. Ikeda A, Iso H, Sasazuki S, Inoue M, Tsugane S, JPHC Study Group (2013) The combination of Helicobacter pylori- and cytotoxin-associated gene-A seropositivity in relation to the risk of myocardial infarction in middle-aged Japanese: the Japan Public Health Center-based study. Atherosclerosis 230(1):67–72. doi:10.1016/j.atherosclerosis.2013.06.013
67. Hiew C, Duggan A, de Malmanche T, Hatton R, Baker F, Attia J, Collins N (2012) Prevalence of Helicobacter pylori positivity in patients undergoing percutaneous coronary intervention. Intern Med J 42(3):289–293. doi:10.1111/j.1445-5994.2010.02260.x
68. Schiele F, Batur MK, Seronde MF, Meneveau N, Sewoke P, Bassignot A, Couetdic G, Caulfield F, Bassand JP (2001) Cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori IgG antibodies and restenosis after stent implantation: an angiographic and intravascular ultrasound study. Heart 85(3):304–311
69. Yetkin G, Ozerol IH, Erbay AR, Durmaz R (2005) Effect of coronary angioplasty on Helicobacter pylori IgG antibody: lack of association between high sensitive C reactive protein and Helicobacter pylori IgG antibody levels. Int J Cardiol 103(3):340–342
70. Carlsson J, Miketic S, Brom J, Ross R, Bachmann H, Tebbe U (2000) Prior cytomegalovirus, Chlamydia pneumoniae or Helicobacter pylori infection and the risk of restenosis after percutaneous transluminal coronary angioplasty. Int J Cardiol 73(2):165–171
71. Kowalski M (2001) Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty, The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol 52((1 Suppl 1)):3–31
72. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, Camm AJ, Northfield TC (2002) Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA). Circulation 106(10):1219–1223
73. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B (1999) Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 20(2):121–127
74. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ (1997) Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96(2):404–407
75. Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, Jogethaei N, da Costa CP, Wagner H, Schömig A (2011) Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357(9274):2085–2089
76. Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M, Pokum S (2001) Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai 84(Suppl 3):S669–S675
77. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, Vuorinen-Markkola H, Nieminen MS, Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group (2002) Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 105(13):1555–1560
78. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C (2000) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102(15):1755–1760
79. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD, Investigators in the WIZARD Study (2003) Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290(11):1459–1466
80. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, Maurer G, Mahrer P, AZACS Investigators (2003) Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the azithromycin in acute coronary syndrome (AZACS) trial: a randomised controlled trial. Lancet 361(9360):809–813
81. Burkhardt U, Zahn R, Höffler U, Siegler KE, Frilling B, Weber M, Gottwik M, Wehr M, Seidel F, Rosocha S, Tebbe U, Senges J (2004) Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised antibiotic therapy in acute myocardial infarction (ANTIBIO) trial. Z Kardiol 93(9):671–678
82. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2005) Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 352(16):1646–1654
83. Manolakis A, Kapsoritakis AN, Potamianos SP (2007) A review of the postulated mechanisms concerning the association of Helicobacter pylori with ischemic heart disease. Helicobacter 12(4):287–297
84. Iriz E, Cirak MY, Engin ED, Zor MH, Erer D, Ozdogan ME, Turet S, Yener A (2008) Detection of Helicobacter pylori DNA in aortic and left internal mammary artery biopsies. Tex Heart Inst J 35(2):130–135
85. Vcev A, Nakić D, Mrden A, Mirat J, Balen S, Ruzić A, Persić V, Soldo I, Matijević M, Barbić J, Matijević V, Bozić D, Radanović B (2007) Helicobacter pylori infection and coronary artery disease. Coll Antropol 31(3):757–760
86. Kilic A, Onguru O, Tugcu H, Kilic S, Guney C, Bilge Y (2006) Detection of cytomegalovirus and Helicobacter pylori DNA in arterial walls with grade III atherosclerosis by PCR. Pol J Microbiol 55(4):333–337
87. Lenzi C, Palazzuoli A, Giordano N, Alegente G, Gonnelli C, Campagna MS, Santucci A, Sozzi M, Papakostas P, Rollo F, Nuti R, Figura N (2006) H. pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. World J Gastroenterol 12(48):7815–7820
88. Vijayvergiya R, Agarwal N, Bahl A, Grover A, Singh M, Sharma M, Khullar M (2006) Association of Chlamydia pneumoniae and Helicobacter pylori infection with angiographically demonstrated coronary artery disease. Int J Cardiol 107(3):428–429
89. Kaplan M, Yavuz SS, Cinar B, Koksal V, Kut MS, Yapici F, Gercekoglu H, Demirtas MM (2006) Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis 10(2):116–123
90. Adiloglu AK, Ocal A, Can R, Duver H, Yavuz T, Aridogan BC (2005) Detection of Helicobacter pylori and Chlamydia pneumoniae DNA in human coronary arteries and evaluation of the results with serologic evidence of inflammation. Saudi Med J 26(7):1068–1074
91. Ahmadnia H, Vossoughinia H, Mansourian E, Gaffarzadegan K (2013) No detection of Helicobacter pylori in atherosclerotic plaques in end stage renal disease patients undergoing kidney transplantation. Indian J Nephrol 23(4):259–263. doi:10.4103/0971-4065.114483
92. Saijo Y, Yoshioka E, Fukui T, Kawaharada M, Sata F, Sato H, Kishi R (2007) H. pylori seropositivity and cytokine gene polymorphisms. World J Gastroenterol 13(33):4445–4451
93. Esser S, Gelbrich G, Brockmeyer N, Goehler A, Schadendorf D, Erbel R, Neumann T, Reinsch N (2013) Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol 102(3):203–213. doi:10.1007/s00392-012-0519-0
94. Skowasch D, Jabs A, Andrié R, Dinkelbach S, Schiele TM, Wernert N, Lüderitz B, Bauriedel G (2004) Pathogen burden, inflammation, proliferation and apoptosis in human in-stent restenosis. Tissue characteristics compared to primary atherosclerosis. J Vasc Res 41(6):525–534
95. Chen BF, Xu X, Deng Y, Ma SC, Tang LQ, Zhang SB, Chen ZF (2013) Relationship between Helicobacter pylori infection and serum interleukin-18 in patients with carotid atherosclerosis. Helicobacter 18(2):124–128. doi:10.1111/hel.12014
96. Shanker J, Kakkar VV (2009) Role of periodontal infection in cardiovascular disease: a current perspective. Arch Med Sci 5(2):125–134
97. Ramdeen N, Aronow WS, Chugh S, Asija A (2008) Patients undergoing coronary angiography because of chest pain with hepatitis C virus seropositivity have a higher prevalence of obstructive coronary artery disease than a control group. Arch Med Sci 4(4):452–454
98. Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM (2013) Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol 102(4):259–268. doi:10.1007/s00392-012-0530-5
99. Collins SM, Denou E, Verdu EF, Bercik P (2009) The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liv Dis 41(12):850–853. doi:10.1016/j.dld.2009.07.023
100. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Taché Y, Wood JD (2006) Fundamentals of neurogastroenterology: basic science. Gastroenterology 130(5):1391–1411
101. Marques AH, Silverman MN, Sternberg EM (2010) Evaluation of stress systems by applying noninvasive methodologies: measurements of neuroimmune biomarkers in the sweat, heart rate variability and salivary cortisol. NeuroImmunoModulation 17(3):205–208. doi:10.1159/000258725
102. Wood JD (2007) Neuropathophysiology of functional gastrointestinal disorders. World J Gastroenterol 13(9):1313–1332
103. Budzyński J, Kłopocka M, Bujak R, Świątkowski M, Sinkiewicz W (2004) Autonomic nervous function in Helicobacter pylori infected patients with atypical chest pain studied by analysis of heart rate variability. Eur J Gastroenterol Hepatol 16(5):451–457
104. Kanbay M, Gür G, Yücel M, Yilmaz U, Boyacioğlu S (2005) Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci 50(7):1228–1231
105. Pellicano R, Oliaro E, Fagoonee S, Astegiano M, Berrutti M, Saracco G, Smedile A, Repici A, Leone N, Castelli A, Luigiano C, Fadda M, Rizzetto M (2009) Clinical and biochemical parameters related to cardiovascular disease after Helicobacter pylori eradication. Int Angiol 28(6):469–473
106. Pellicano R (2010) Lipid profile and Helicobacter pylori infection. J Atheroscler Thromb 17(11):1199–1200
107. Elizalde JI, Piqué JM, Moreno V, Morillas JD, Elizalde I, Bujanda L, De Argila CM, Cosme A, Castiella A, Ros E, Group of Study on Oesophageal and Gastric Diseases from The Spainish Gastroenterological Association (2002) Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. Aliment Pharmacol Ther 16(3):577–586
108. Huang B, Chen Y, Xie Q, Lin G, Wu Y, Feng Y, Li J, Zhuo Y, Zhang P (2011) CagA-positive Helicobacter pylori strains enhanced coronary atherosclerosis by increasing serum OxLDL and HsCRP in patients with coronary heart disease. Dig Dis Sci 56(1):109–114. doi:10.1007/s10620-010-1274-6
109. Satoh K, Hirayama T, Takano K, Suzuki-Inoue K, Sato T, Ohta M, Nakagomi J, Ozaki Y (2013) VacA, the vacuolating cytotoxin of Helicobacter pylori, binds to multimerin 1 on human platelets. Thromb J 11(1):23. doi:10.1186/1477-9560-11-23
110. Budzyński J (2011) Angina-like chest pain as a symptom of digestive tract disorders. In: Piscione F (ed) Angina pectoris. InTech, Rijeka, pp 35–70 (ISBN 978-953-307-581-5)
111. Marietti M, Gasbarrini A, Saracco G, Pellicano R (2013) Helicobacter pylori infection and diabetes mellitus: the 2013 state of art. Panminerva Med 55(3):277–281
112. Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M (1996) Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. Heart 75(13):568–572
113. Gentile S, Turco S, Oliviero B, Torella R (1998) The role of autonomic neuropathy as a risk factor of Helicobacter pylori infection in dyspeptic patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 42(1):41–48
114. Zhou X, Zhang C, Wu J, Zhang G (2013) Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract 99(2):200–208. doi:10.1016/j.diabres.2012.11.012
115. 13C-Urea breath test. BMC Public Health 13:1215. doi:10.1186/1471-2458-13-1215
116. Wang F, Liu J, Lv Z (2013) Association of Helicobacter pylori infection with diabetes mellitus and diabetic nephropathy: a meta-analysis of 39 studies involving more than 20,000 participants. Scand J Infect Dis 45(12):930–938. doi:10.3109/00365548.2013.844351
117. Jafri W, Yakoob J, Abid S, Awan S, Siddiqui S, Jafri F, Hamid S, Nizami SQ (2013) Seroprevalence of hepatitis E and Helicobacter pylori in a low socioeconomic area of a metropolitan city in a developing country. Br J Biomed Sci 70(1):27–30
118. Valliani A, Khan F, Chagani B, Khuwaja AK, Majid S, Hashmi S, Nanji K, Valliani S (2013) Factors associated with Helicobacter pylori infection, results from a developing country, Pakistan. Asian Pac J Cancer Prev 14(1):53–56
119. Wang JY, Wang CY, Juang SY, Huang KY, Chou P, Chen CW, Lee CC (2014) Low socioeconomic status increases short-term mortality of acute myocardial infarction despite universal health coverage. Int J Cardiol. doi:10.1016/j.ijcard.2013.12.082
120. Murray LJ, Bamford KB, O'Reilly DP, McCrum EE, Evans AE (1995) Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. Br Heart J 74(5):497–501
121. Pellicano R, Mazzarello MG, Morelloni S, Allegri M, Arena V, Ferrari M, Rizzetto M, Ponzetto A (1999) Acute myocardial infarction and Helicobacter pylori seropositivity. Int J Clin Lab Res 29(4):141–144
122. Brown LM (2000) Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22(2):283–297
123. Ridker PM, Danesh J, Youngman L, Collins R, Stampfer MJ, Peto R, Hennekens CH (2001) A prospective study of Helicobacter pylori seropositivity and the risk for future myocardial infarction among socioeconomically similar U.S. men. Ann Intern Med 135(3):184–188
124. Wu HQ, Tang Y, Zhang X, Wei XH, Wang HQ, Zhang WT, Zhang GL (2012) Effect of Helicobacter pylori infection on platelet activation and coagulation function in patients with acute cerebral infarction. Zhejiang Da XueXueBao Yi Xue Ban 41(5):547–552
125. Stasi R, Provan D (2008) Helicobacter pylori and Chronic ITP. Hematology Am Soc Hematol Educ Program 1:206–211. doi:10.1182/asheducation-2008.1.206
126. Corcoran PA, Atherton JC, Kerrigan SW, Wadstrom T, Murray FE, Peek RM, Fitzgerald DJ, Cox DM, Byrne MF (2007) The effect of different strains of Helicobacter pylori on platelet aggregation. Can J Gastroenterol 21(6):367–370
127. Corcoran PA, McGuane DE, McGrath AM, Burke CM, Byrne MF (2009) Blood group O and vWf expression may be involved in development of peptic ulcer disease secondary to Helicobacter pylori infection. Med Hypotheses 73(3):338–339. doi:10.1016/j.mehy.2008.10.038
128. Byrne MF, Kerrigan SW, Corcoran PA, Atherton JC, Murray FE, Fitzgerald DJ, Cox DM (2003) Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 124(7):1846–1854
129. Fagoonee S, De Angelis C, Elia C, Silvano S, Oliaro E, Rizzetto M, Pellicano R (2010) Potential link between Helicobacter pylori and ischemic heart disease: does the bacterium elicit thrombosis? Minerva Med 101(2):121–125
130. Bai Y, Wang Z, Bai X, Yu Z, Cao L, Zhang W, Ruan C (2009) Cross-reaction of antibody against Helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura. Int J Hematol 89(2):142–149. doi:10.1007/s12185-008-0247-4
131. McNicol A, Zhu R, Pesun R, Pampolina C, Jackson EC, Bowden GH, Zelinski T (2006) A role for immunoglobulin G in donor-specific Streptococcus sanguis-induced platelet aggregation. Thromb Haemost 95(2):288–293
132. Yeh JJ, Tsai S, Wu DC, Wu JY, Liu TC, Chen A (2010) P-selectin-dependent platelet aggregation and apoptosis may explain the decrease in platelet count during Helicobacter pylori infection. Blood 115(21):4247–4253. doi:10.1182/blood-2009-09-241166
133. Wassermann GE, Olivera-Severo D, Uberti AF, Carlini CR (2010) Helicobacter pylori urease activates blood platelets through a lipoxygenase-mediated pathway. J Cell Mol Med 14(7):2025–2034. doi:10.1111/j.1582-4934.2009.00901.x
134. Ahn ER, Tiede MP, Jy W, Bidot CJ, Fontana V, Ahn YS (2006) Platelet activation in Helicobacter pylori-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. Acta Haematol 116(1):19–24
135. Singla S, Sachdeva R, Uretsky BF (2012) Platelet activation in Helicobacter pylori-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. J Am Coll Cardiol 60(1):2005–2016
136. To AC, Armstrong G, Zeng I, Webster MW (2009) Noncardiac surgery and bleeding after percutaneous coronary intervention. Circ Cardiovasc Interv 2(3):213–221. doi:10.1161/CIRCINTERVENTIONS.108.830158
137. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG) (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33(13):1635–1701. doi:10.1093/eurheartj/ehs092
138. Delaney JA, Opatrny L, Brophy JM, Suissa S (2007) Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 177(4):347–351
139. Watanabe M, Kawai T, Takata Y, Yamashina A (2011) Gastric mucosal damage evaluated by transnasal endoscopy and QOL assessments in ischemic heart disease patients receiving low-dose aspirin. Intern Med 50(6):539–544
140. Lin KJ, Hernández-Díaz S, García Rodríguez LA (2011) Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 141(1):71–79. doi:10.1053/j.gastro.2011.03.049
141. Wrigley BJ, Tapp LD, Shantsila E, Lip GY (2010) Antithrombotic therapy in anticoagulated patients with atrial fibrillation presenting with acute coronary syndromes and/or undergoing percutaneous coronary intervention/stenting. Pol Arch Med Wewn 120(7–8):290–293
142. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blömstrom-Lundqvist C, Colonna P, DeSutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbüchel H, Heldal M,Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW; ESC Committee for Practice Guidelines (CPG) (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33(21):2719-2747. doi:10.1093/eurheartj/ehs253
143. Häuptle R, Weilenmann D, Schneider T, Haile SR, Ammann P, Knellwolf C, Borovicka J (2012) Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study. Wien Med Wochenschr 162(3–4):67–73. doi:10.1007/s10354-012-0056-5
144. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999–3054. doi:10.1093/eurheartj/ehr236
145. Lai KC, Chu KM, Hui WM, Wong BC, Hung WK, Loo CK, Hu WH, Chan AO, Kwok KF, Fung TT, Wong J, Lam SK (2006) Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 4(7):860–865
146. Crooks CJ, West J, Card TR (2013) Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 144(7):1384–1393. doi:10.1053/j.gastro.2013.02.040
147. Uotani T, Sugimoto M, Nishino M, Kodaira C, Yamade M, Sahara S, Yamada T, Osawa S, Sugimoto K, Tanaka T, Umemura K, Watanabe H, Miyajima H, Furuta T (2012) Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. Clin Gastroenterol Hepatol 10(8):879–885. doi:10.1016/j.cgh.2012.04.016
148. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP, COGENT Investigators (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363(20):1909–1917. doi:10.1056/NEJMoa1007964
149. http://clinicaltrials.gov/show/NCT01506986
150. Gokturk HS, Demir M, Unler GK, Erbayrak M, Sakalli M, Yilmaz U (2011) Does long-term aspirin use have any effect on Helicobacter pylori eradication? Am J Med Sci 342(1):15–19. doi:10.1097/MAJ.0b013e3182174cf1
151. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 17(3):165–184. doi:10.1007/s40291-013-0028-5
152. Kasprzak M, Koziński M, Bielis L, Boinska J, Plazuk W, Marciniak A, Budzyński J, Siller-Matula J, Rość D, Kubica J (2009) Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 16(6):535–544
153. Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ (2012) A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 35(7):810–818. doi:10.1111/j.1365-2036.2012.05014.x
154. Jinda S, Nakatani K, Nishioka J, Yasuda K, Soya Y, Hayashi A, Wada H, Nobori T (2011) Personalized treatment in the eradication therapy for Helicobacter pylori. Int J Mol Med 27(2):255–261. doi:10.3892/ijmm.2010.569
155. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G (2007) The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12(Suppl 2):32–38
156. Navarese EP, Austin D, Gurbel PA, Andreotti F, Tantry U, James S, Buffon A, Koziński M, Obońska K, Bliden K, Jeong YH, Kubica J, Kunadian V (2013) Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomized controlled trials. Clin Res Cardiol 102(4):279–287. doi:10.1007/s00392-012-0532-3
157. Gisbert JP, Trapero M, Calvet X, Mendoza J, Quesada M, Güell M, Pajares JM (2004) Evaluation of three different tests for the detection of stool antigens to diagnose Helicobacter pylori infection in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther 19(8):923–929
158. Watanabe T, Tanigawa T, Nadatani Y, Nagami Y, Sugimori S, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Koike T, Arakawa T (2013) Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis 45(5):390–395. doi:10.1016/j.dld.2012.12.005
159. Muraki M, Fujiwara Y, Machida H, Okazaki H, Sogawa M, Yamagami H, Tanigawa T, Shiba M, Watanabe K, Tominaga K, Watanabe T, Arakawa T (2014) Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users. Scand J Gastroenterol 49(3):267–273. doi:10.3109/00365521.2014.880182
160. Nseir W, Diab H, Mahamid M, Abu-Elheja O, Samara M, Abid A, Mograbi J (2012) Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate–a placebo-controlled study. Aliment Pharmacol Ther 36(3):231–238. doi:10.1111/j.1365-2036.2012.05161.x